While the presence of CDKN2A loss is gaining increasing recognition as a key diagnostic and prognostic marker in gliomas and meningiomas, and is an inclusion criterion for some clinical trials, its molecular detection remains expensive, time consuming and not widely available. This evidence concerns the gene CDKN2A and central nervous system cancer.